Non-inferiority trials test whether a new product is not unacceptably worse than a product already in use. This paper introduces concepts related to non-inferiority, and discusses the regulatory views of both the European Medicines Agency and the United States Food and Drug Administration.
No takes yet. Share an insight, caveat, or question.
Schumi et al. (2011) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: